AIP
SMMT icon

Ameritas Investment Partners’s Summit Therapeutics SMMT Stock Holding History

Ameritas Investment Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,621
Closed -$186K – 3330
2025
Q1 		$186K Hold
9,621
– – 0.01% 1306
2024
Q4 		$172K Buy
9,621
+1,044
+12% +$20.2K 0.01% 1418
2024
Q3 		$188K Hold
8,577
– – 0.01% 1366
2024
Q2 		$66.9K Sell
8,577
-3,042
-26% -$16.4K ﹤0.01% 1976
2024
Q1 		$48.1K Buy
11,619
+2,050
+21% +$8.15K ﹤0.01% 2168
2023
Q4 		$25K Hold
9,569
– – ﹤0.01% 2490
2023
Q3 		$17.9K Hold
9,569
– – ﹤0.01% 2596
2023
Q2 		$24K Buy
+9,569
New +$17.5K ﹤0.01% 2470
2022
Q2 		– Sell
-1,762
Closed -$4K – 3216
2022
Q1 		$4K Hold
1,762
– – ﹤0.01% 3005
2021
Q4 		$5K Hold
1,762
– – ﹤0.01% 3045
2021
Q3 		$9K Hold
1,762
– – ﹤0.01% 2970
2021
Q2 		$13K Buy
+1,762
New +$11.6K ﹤0.01% 2893

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Ameritas Investment Partners's SMMT Position: Q2 2025 in Review

Ameritas Investment Partners sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 9,621 shares — an estimated $186K sold.

Ameritas Investment Partners first reported a position in SMMT in Q2 2021 and held it in 12 quarters. The position peaked at $188K in Q3 2024. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

  • Ameritas Investment Partners reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ameritas Investment Partners sold 9,621 Summit Therapeutics shares in Q2 2025, an estimated $186K.
  • Ameritas Investment Partners first reported a position in Summit Therapeutics in Q2 2021 and held it in 12 quarters.
  • Ameritas Investment Partners's Summit Therapeutics position peaked at $188K in Q3 2024.
  • 238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.